Overview

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

Multicenter Phase II study on Decitabine-Carboplatin combination in platinum resistant ovarian cancer patients. Patients will receive study treatment until disease progression is documented, extraordinary medical circumstances occur, intolerable toxicities occur, or the patient withdraws consent.

Phase:

Phase 2

Details

Lead Sponsor:

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Treatments:

Azacitidine
Carboplatin
Decitabine
Doxorubicin
Gemcitabine
Liposomal doxorubicin
Paclitaxel